Humana Inc (HUM) Shares Sold by Fort Washington Investment Advisors Inc. OH

Fort Washington Investment Advisors Inc. OH lowered its stake in shares of Humana Inc (NYSE:HUM) by 26.7% during the third quarter, Holdings Channel reports. The fund owned 1,026 shares of the insurance provider’s stock after selling 374 shares during the quarter. Fort Washington Investment Advisors Inc. OH’s holdings in Humana were worth $347,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Alps Advisors Inc. boosted its stake in shares of Humana by 10.0% during the second quarter. Alps Advisors Inc. now owns 3,675 shares of the insurance provider’s stock valued at $1,094,000 after acquiring an additional 334 shares during the last quarter. Sio Capital Management LLC acquired a new stake in shares of Humana during the second quarter valued at $5,296,000. Intact Investment Management Inc. acquired a new stake in shares of Humana during the third quarter valued at $220,000. Columbus Hill Capital Management L.P. boosted its stake in shares of Humana by 57.6% during the second quarter. Columbus Hill Capital Management L.P. now owns 150,759 shares of the insurance provider’s stock valued at $44,870,000 after acquiring an additional 55,100 shares during the last quarter. Finally, DNB Asset Management AS boosted its stake in shares of Humana by 4.2% during the third quarter. DNB Asset Management AS now owns 30,023 shares of the insurance provider’s stock valued at $10,163,000 after acquiring an additional 1,209 shares during the last quarter. 92.73% of the stock is currently owned by institutional investors and hedge funds.

A number of analysts recently commented on HUM shares. Royal Bank of Canada reaffirmed a “hold” rating and set a $318.00 price objective on shares of Humana in a research note on Thursday, August 2nd. Jefferies Financial Group increased their price objective on Humana from $356.00 to $372.00 and gave the company a “buy” rating in a research note on Thursday, August 2nd. Morgan Stanley increased their price objective on Humana from $362.00 to $365.00 and gave the company an “overweight” rating in a research note on Thursday, August 2nd. Bank of America increased their price objective on Humana from $338.00 to $375.00 and gave the company a “buy” rating in a research note on Thursday, August 2nd. Finally, Piper Jaffray Companies reaffirmed a “buy” rating and set a $355.00 price objective on shares of Humana in a research note on Thursday, August 2nd. Seven investment analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. Humana has a consensus rating of “Buy” and an average price target of $352.30.

In other Humana news, CEO Bruce D. Broussard sold 18,000 shares of the firm’s stock in a transaction dated Monday, September 10th. The stock was sold at an average price of $328.66, for a total value of $5,915,880.00. Following the sale, the chief executive officer now directly owns 71,085 shares of the company’s stock, valued at approximately $23,362,796.10. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Roy A. Beveridge sold 4,622 shares of Humana stock in a transaction dated Thursday, November 8th. The shares were sold at an average price of $341.06, for a total value of $1,576,379.32. Following the completion of the transaction, the insider now directly owns 10,621 shares in the company, valued at $3,622,398.26. The disclosure for this sale can be found here. 0.60% of the stock is currently owned by company insiders.

Shares of NYSE:HUM opened at $319.73 on Friday. The company has a current ratio of 1.68, a quick ratio of 1.68 and a debt-to-equity ratio of 0.45. Humana Inc has a 12-month low of $231.90 and a 12-month high of $355.88. The stock has a market capitalization of $43.86 billion, a price-to-earnings ratio of 22.90, a price-to-earnings-growth ratio of 1.52 and a beta of 1.03.

Humana (NYSE:HUM) last issued its quarterly earnings results on Wednesday, November 7th. The insurance provider reported $4.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.29 by $0.29. Humana had a return on equity of 19.10% and a net margin of 2.70%. The firm had revenue of $14.21 billion for the quarter, compared to analyst estimates of $13.97 billion. During the same period last year, the company earned $3.39 EPS. Sell-side analysts expect that Humana Inc will post 14.43 earnings per share for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, January 25th. Shareholders of record on Monday, December 31st will be paid a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a yield of 0.63%. The ex-dividend date is Friday, December 28th. Humana’s payout ratio is 17.08%.

TRADEMARK VIOLATION WARNING: “Humana Inc (HUM) Shares Sold by Fort Washington Investment Advisors Inc. OH” was originally posted by WKRB News and is owned by of WKRB News. If you are accessing this report on another site, it was illegally stolen and republished in violation of United States & international trademark & copyright law. The legal version of this report can be read at https://www.wkrb13.com/2018/11/18/humana-inc-hum-shares-sold-by-fort-washington-investment-advisors-inc-oh.html.

About Humana

Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company operates through four segments: Retail; Group and Specialty; Healthcare Services; and Individual Commercial. The Retail segment offers Medicare and supplemental benefit plans to individuals or through group accounts.

Featured Story: Understanding Market Liquidity

Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc (NYSE:HUM).

Institutional Ownership by Quarter for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply